1. Aupérin, A., Pechoux, C., Rolland, E., Curran, W., Furuse, K., Fournel, P. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 2181–2190 (2010).
2. Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017).
3. Adizie, J. B., Khakwani, A., Beckett, P., Navani, N., Harden, S. & Woolhouse, I. S98 treatment patterns and survival outcomes of stage iiia (n2) non -small cell lung cancer in England. Thorax 72, A59–A60 (2017).
4. O’Rourke, N., Roqué i Figuls, M., Farré Bernadó, N. & Macbeth, F. Concurrent chemoradiotherapy in non‐small cell lung cancer. Cochrane Database Syst. Rev. 16, CD002140 (2010).
5. Curran, W. J., Paulus, R., Langer, C. J., Komaki, R., Lee, J. S., Hauser, S. et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J. Natl. Cancer Inst. 103, 1452–1460 (2011).